1
|
Grujičić D, Mirkov L, Banković D, Virijević K, Marinković D, Milošević-Djordjević O. Homozygous-Recessive Characteristics as a Biomarker of Predisposition for COVID-19. Clin Nurs Res 2023; 32:589-600. [PMID: 36695163 PMCID: PMC9902784 DOI: 10.1177/10547738221147754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Coronavirus disease (COVID-19), a new form of severe acute respiratory syndrome, has caused a global pandemic. The aim of this study was to analyze homozygous-recessive characteristics (HRC) in the group of COVID-19 patients, considering their gender, forms of the disease (mild and severe symptoms), risk factors: hypertension, diabetes mellitus type 2, hyperlipidemia, smoking habits, and the distribution of ABO blood group. Using the HRC test, we analyzed 20 HRCs in a sample of 321 individuals: 205 patients and 116 controls. The average HRC in patients was significantly higher than controls, as well as in patients with severe symptoms compared to patients with mild symptoms. The patients with higher HRC (cut-off ≤5.5) experienced a significantly increased risk of disease of 2.3 times (OR = 2.315, p < .0005). Our results indicate that the HRC test could be used as a screening in recognizing predisposition for COVID-19.
Collapse
|
2
|
Koç S, Karcioglu Batur L. Association between ABO blood types and the prognosis and mortality rates in patients with severe COVID-19 admitted in the intensive care unit of a tertiary-level hospital in Turkey. Curr Med Res Opin 2022; 38:1515-1520. [PMID: 35848063 DOI: 10.1080/03007995.2022.2101806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVES There is limited number of data showing possible correlation between ABO blood types and prognosis and mortality of COVID-19 patients. It was aimed to investigate whether ABO blood group type affects the prognosis and mortality rates in patients with severe COVID-19 hospitalized in the ICU (intensive care unit) of a tertiary-level hospital in Turkey. METHODS The data of 273 patients with diagnosis of severe COVID-19 who were admitted to ICU from April 2020 through June 2021 and in an age range between 25-93 years were evaluated in this retrospective study. RESULTS Blood group distribution was 47.3, 13.2, 10.6 and 28.9% for groups A, B, AB, and O, respectively. As a respiratory status at admission to ICU, the ratio of intubation patients with blood type O was significantly higher than of other groups while most of patients in group A achieved spontaneous respiration without any mechanical ventilator (p = .0168). The mean neutrophil ratio, NLR, concentrations of procalcitonin, lactate, urea and ferritin significantly increased in the serum of patients with type O (p < .01 for all except p = .016 for the ferritin). The weaning duration was longest among patients with blood group O while the hospitalization duration was longest among patients with group AB; however, there was not significant difference (p > .05). The highest mortality rate was calculated in group AB as 68.97% and lowest was 47.2% in group B without any statistical difference (p > .05). CONCLUSION ABO blood types carry different association risk factors for the prognosis of severe COVID-19 patients hospitalized in ICU. Specifically, blood group O was correlated with an increased risk of deterioration of respiratory status including intubation and elevation of laboratory findings whereas it did not affect the risk of increased mortality.
Collapse
Affiliation(s)
- Suna Koç
- Department of Anesthesiology and Reanimation, Biruni University Medical Faculty, Istanbul, Turkey
| | - Lutfiye Karcioglu Batur
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul, Turkey
| |
Collapse
|
3
|
Díaz-Salazar S, Navas R, Sainz-Maza L, Fierro P, Maamar M, Artime A, Basterrechea H, Petitta B, Pini S, Olmos JM, Ramos C, Pariente E, Hernández JL. Blood group O is associated with post-COVID-19 syndrome in outpatients with a low comorbidity index. Infect Dis (Lond) 2022; 54:897-908. [DOI: 10.1080/23744235.2022.2115548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- Sara Díaz-Salazar
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Raquel Navas
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
| | - Laura Sainz-Maza
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
| | - Patricia Fierro
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Meryam Maamar
- Emergency Service. Osakidetza. Servicio Vasco de Salud, Bilbao, Spain
| | - Arancha Artime
- El Llano - Primary Care Center. SESPA- Servicio Asturiano de Salud, Gijón, Spain
| | - Héctor Basterrechea
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Benedetta Petitta
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
| | - Stefanie Pini
- Hospital at Home Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - José Manuel Olmos
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
- Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla. Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| | - Carmen Ramos
- Camargo Costa – Primary Care Center. Servicio Cántabro de Salud, Maliaño, Spain
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
| | - Emilio Pariente
- Camargo Interior - Primary Care Center. Servicio Cántabro de Salud, Muriedas, Spain
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
| | - José Luis Hernández
- Depto. de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
- Servicio de Medicina Interna, Hospital Universitario Marqués de Valdecilla. Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain
| |
Collapse
|
4
|
Kabrah SM, Abuzerr SS, Baghdadi MA, Kabrah AM, Flemban AF, Bahwerth FS, Assaggaf HM, Alanazi EA, Alhifany AA, Al-Shareef SA, Alsabban WH, Khan AA, Alzhrani H, Jambi LK, Alsafi RT, Aslam A, Kabrah HM, Babalghith AO, Halawani AJ. Susceptibility of ABO blood group to COVID-19 infections: clinico-hematological, radiological, and complications analysis. Medicine (Baltimore) 2021; 100:e28334. [PMID: 34967364 PMCID: PMC8718246 DOI: 10.1097/md.0000000000028334] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 11/30/2021] [Indexed: 01/05/2023] Open
Abstract
In the wake of the COVID-19 pandemic, research indicates that the COVID-19 disease susceptibility varies among individuals depending on their ABO blood groups. Researchers globally commenced investigating potential methods to stratify cases according to prognosis depending on several clinical parameters. Since there is evidence of a link between ABO blood groups and disease susceptibility, it could be argued that there is a link between blood groups and disease manifestation and progression. The current study investigates whether clinical manifestation, laboratory, and imaging findings vary among ABO blood groups of hospitalized confirmed COVID-19 patients.This retrospective cohort study was conducted between March 1, 2020 and March 31, 2021 in King Faisal Specialist Hospital and Research Centre Riyadh and Jeddah, Saudi Arabia. Demographic information, clinical information, laboratory findings, and imaging investigations were extracted from the data warehouse for all confirmed COVID-19 patients.A total of 285 admitted patients were included in the study. Of these, 81 (28.4%) were blood group A, 43 (15.1%) were blood group B, 11 (3.9%) were blood group AB, and 150 (52.6%) were blood group O. This was almost consistent with the distribution of blood groups among the Saudi Arabia community. The majority of the study participants (79.6% [n = 227]) were asymptomatic. The upper respiratory tract infection (P = .014) and shortness of breath showed statistically significant differences between the ABO blood group (P = .009). Moreover, the incidence of the symptoms was highly observed in blood group O followed by A then B except for pharyngeal exudate observed in blood group A. The one-way ANOVA test indicated that among the studied hematological parameters, glucose (P = .004), absolute lymphocyte count (P = .001), and IgA (P = .036) showed statistically significant differences between the means of the ABO blood group. The differences in both X-ray and computed tomography scan findings were statistically nonsignificant among the ABO age group. Only 86 (30.3%) patients were admitted to an intensive care unit, and the majority of them were blood groups O 28.7% (n = 43) and A 37.0% (n = 30). However, the differences in complications' outcomes were statistically nonsignificant among the ABO age group.ABO blood groups among hospitalized COVID-19 patients are not associated with clinical, hematological, radiological, and complications abnormality.
Collapse
Affiliation(s)
- Saeed M. Kabrah
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Samer S. Abuzerr
- Visiting Scholar with the School of Public Health, Department of Social and Preventive Medicine, University of Montreal, Montreal, Canada
- Quality Improvement and Infection Control Unit, Ministry of Health, Gaza, Palestine
| | - Mohammed A. Baghdadi
- Research Centre, King Faisal Specialist Hospital and Research Centre Jeddah, Kingdom of Saudi Arabia
| | - Ahmed M. Kabrah
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Arwa F. Flemban
- Pathology Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Fayez S. Bahwerth
- Laboratory and Blood Bank Department, King Faisal Hospital, Makkah, Kingdom of Saudi Arabia
| | - Hamza M. Assaggaf
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Eisa A. Alanazi
- Computer Science Department, Faculty of Computer and Information System, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Abdullah A. Alhifany
- Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Sarah A. Al-Shareef
- Computer Science Department, Faculty of Computer and Information System, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Wesam H. Alsabban
- Information System Department, Faculty of Computer and Information Systems, Umm Al Qura University, Makkah, Kingdom of Saudi Arabia
| | - Anmar A. Khan
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Hissah Alzhrani
- Mathematical Sciences Department, Faculty of Applied Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Layal K. Jambi
- Radiological Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Radi T. Alsafi
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Akhmed Aslam
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Hebah M. Kabrah
- Laboratory and Blood Bank Department, Al Noor Specialist Hospital, Makkah, Kingdom of Saudi Arabia
| | - Ahmad O. Babalghith
- Medical Genetic Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| | - Amr J. Halawani
- Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
| |
Collapse
|
5
|
Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-González AD, Ferrando-Rubert S, Ferrer-Abad G, Sánchez-Urbano M, Aparisi-Esteve L, Badenes-Marques G, Cervera-Ferrer B, Clerig-Arnau U, Dols-Bernad C, Fontal-Carcel M, Gomez-Lanas L, Jovani-Sales D, León-Domingo MC, Llopico-Vilanova MD, Moros-Blasco M, Notari-Rodríguez C, Ruíz-Puig R, Valls-López S, Arnedo-Pena A. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph181910039. [PMID: 34639344 PMCID: PMC8507737 DOI: 10.3390/ijerph181910039] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 09/06/2021] [Accepted: 09/16/2021] [Indexed: 12/16/2022]
Abstract
After a COVID-19 outbreak in the Falles festival of Borriana (Spain) during March 2020, a cohort of patients were followed until October 2020 to estimate complications post-COVID-19, considering ABO blood groups (ABO). From 536 laboratory-confirmed cases, 483 completed the study (90.1%) carried by the Public Health Center of Castelló and the Emergency and Microbiology and Clinical Analysis of Hospital de la Plana Vila-real. The study included ABO determination and telephone interviews of patients. The participants had a mean age of 37.2 ± 17.1 years, 300 females (62.1%). ABO were O (41.4%), A (45.5%), B (9.1%), and AB (3.9%). We found no difference in the incidence of COVID-19 infections. A total of 159 (32.9%) patients reported one or more post-COVID-19 complications with divergent incidences after adjustment: O (32.3%), A (32.6%), B (54.1%), and AB (27.6%); B groups had more complications post-COVID-19 when compared with O group (adjusted relative risk [aRR] 95% confidence interval [CI] 1.68, 95% CI 1.24–2.27), and symptoms of fatigue (1.79, 95% CI 1.08–2.95), myalgia (2.06, 95% CI 1.10–3.84), headache (2.61, 95% CI 1.58–4.31), and disorder of vision (4.26 95% CI 1.33–13.60). In conclusion, we observed significant differences in post-COVID-19 complications by ABO, with a higher incidence in B group. Additional research is justified to confirm our results.
Collapse
Affiliation(s)
- Salvador Domènech-Montoliu
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Paula Vidal-Utrillas
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Marta Latorre-Poveda
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Alba Del Rio-González
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Sara Ferrando-Rubert
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Gema Ferrer-Abad
- Health Centers I and II, Health Department 2, 12530 Borriana, Spain; (P.V.-U.); (A.D.R.-G.); (S.F.-R.); (G.F.-A.)
| | - Manuel Sánchez-Urbano
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | - Gema Badenes-Marques
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Belén Cervera-Ferrer
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Ursula Clerig-Arnau
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Lorna Gomez-Lanas
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - David Jovani-Sales
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | - Maria Dolores Llopico-Vilanova
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | | | | | - Raquel Ruíz-Puig
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Sonia Valls-López
- Emergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain; (S.D.-M.); (M.L.-P.); (M.S.-U.); (G.B.-M.); (B.C.-F.); (U.C.-A.); (L.G.-L.); (D.J.-S.); (M.D.L.-V.); (R.R.-P.); (S.V.-L.)
| | - Alberto Arnedo-Pena
- Public Health Center, Health Department 2, 12003 Castello de la Plana, Spain;
- Department of Health Science, Public University Navarra, 31008 Pamplona, Spain
- Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Correspondence: or ; Tel.: +35-622-573979
| |
Collapse
|